Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Histogenics Corporation
Deal Watch: Gilead To Use Insitro’s AI/Functional Genomics Tech For NASH Targets
Start-up Insitro will attempt to optimize up to five NASH targets for Gilead under three-year alliance. Catalent buys gene therapy CDMO Paragon for $1.2bn, Boehringer partners with PureTech in GI cancer, while Fibrocell inks gene therapy pact with Castle Creek.
Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks
Finance Watch has noted $1.1bn worth of venture capital deals so far in 2019. Meanwhile, public offerings continue to be muted by the US government shutdown, though Revance and others sold shares. Also, Five Prime and others reveal layoffs and strategic shifts.
Failed Phase III For NeoCart May Still Fly With US FDA, Histogenics Argues
Agency guidance does not require coprimary, dual responder endpoint for drugs developed for knee cartilage repair, so in Histogenics' view, door is still open for approval.
Deals Shaping The Medical Industry, February 2018
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.
- Implantable Devices
- Gene Therapy, Cell Therapy
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.